Scaling Up African Vaccine Manufacturing Capacity - Perspectives from the African

This alarming shortfall served as a wake-up complement all the excellent efforts of the various call and prompted renewed efforts to build vaccine- stakeholders supporting the future of the African manufacturing capacity and capabilities in Africa. [...] made in the past 18 months, in regards to funding, Previous crises have shown the dangers of Africa’s manufacturing partnerships, and review of the current over-reliance on external supply chains, and the procurement mechanism. [...] Covid-19) Given the complexities described above and the Unsurprisingly, it turns out that the profitability of narrow path to economic viability, stakeholders need investment in end-to-end facilities varies greatly, to move astutely, ensuring that investments are depending on the technology platform and the directed only to sensible manufacturing projects, and vaccine complexity. [...] African DCVMs account for 75% of the volume and 36% of the value, and MNCs account for 24% of The second prerequisite identified by manufacturers – a the volume and 64% of the value.11 Gavi has already specific financial mechanism – would cover the price announced its willingness to “update the Alliance’s premium of African vaccine manufacturing (see section market shaping to place a higher value. [...] Our survey has revealed consistent support for the As indicated in the preamble to this report, the work done by PAVM – in particular, the identified manufacturers’ views shared in this report are not challenges and defined enablers in the FFA (namely, meant to steer the full set of activities and initiatives to access to finance, agenda-setting and coordination, support the African vaccine manufa.